Bio-Techne Corp. is navigating a tough financial period after a significant earnings miss in Q3 2026, where it reported $311.4 million in revenue and adjusted EPS of $0.53. Despite a 2% year-over-year decline in organic revenue, industry analysts expect a recovery in 2026, driven by promising demand from large pharma and growth in its spatial biology segment. With a recent rebound in stock price and improved GAAP operating margins reaching 24.2%, analysts are targeting a median price of $68.69, projecting over 50% upside from current levels.
“Bio-Techne · is · a global life sciences company · true”
“Bio-Techne · empowers · scientific discovery · true”
“Bio-Techne · advances · human health · true”
“Bio-Techne Corp. · engages in the · development, manufacture and sale of biotechnology reagents and instruments · for the research and clinical diagnostic markets”
“Bio-Techne Corp. · operates through the · Biotechnology, Protein Platforms, Diagnostics, and Corporate segments”
“Bio-Techne Corp. · was founded on · 1976”
“Bio-Techne Corp. · is headquartered in · Minneapolis, MN”
“Bio-Techne Corp. · as of April 2026 · has 3,000 employees”
“Bio-Techne · declined · significantly · over the past month following a Q3 2026 earnings miss”
“Bio-Techne · has begun · a minor three-day rebound”
“Bio-Techne · has seen · weak revenue and adjusted EPS growth · pressured price action”
“Bio-Techne · is seeing · robust growth · in its spatial biology segment, which grew in the mid-teens”
